NOVOLIN N (human insulin) by Novo Nordisk. Approved for insulin [epc]. First approved in 1991.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
NOVOLIN N is a human insulin (NPH) injectable formulation approved in 1991 for the treatment of diabetes mellitus. It is a basal insulin that provides intermediate-acting glycemic control, typically used in combination with rapid-acting insulins or oral agents. The drug works by facilitating glucose uptake in peripheral tissues and suppressing hepatic glucose production.
Product approaching loss of exclusivity with $53M in annual Part D spending; brand teams are shifting to defensive positioning and cost optimization strategies.
Insulin
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Defining the Human Insulin Resistance Molecular Network; SIGNATURE
A Trial to Investigate Post Prandial Blood Glucose Control With Fast-acting Human Insulin HinsBet® Compared to Insulin Lispro (Humalog®) and Regular Human Insulin (Huminsulin® Normal) After Ingestion of a Standardized Meal in Subjects With T1DM
A Double-blinded, Randomised, Three-period Crossover Euglycaemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Human Insulin, Human Insulin (Huminsulin® Normal) and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes
A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue
Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus
Worked on NOVOLIN N at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on NOVOLIN N positions pharma professionals in a defensive, cost-focused commercial environment where success is measured by slowing share erosion and maximizing margins before generic entry. Career trajectory is limited to lateral moves within managed decline roles; advancement typically requires transition to growth-stage products or strategic accounts.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo